ORBIMED ADVISORS LLC 4
4 · Q32 Bio Inc. · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
Q32 Bio (QTTB) 10% Owner OrbiMed Advisors Buys $15M Stock
What Happened
- OrbiMed Advisors LLC — reported as a 10% owner — purchased a total of 1,875,000 shares of Q32 Bio Inc. (QTTB) on May 28, 2026. The purchases were two tranches: 1,250,000 shares and 625,000 shares, each at $8.00 per share, for a combined purchase price of $15,000,000. The filing indicates these shares were bought from the issuer in private placements (footnote F1). This is a purchase (potentially viewed as a bullish signal), not a sale.
Key Details
- Transaction date: May 28, 2026
- Price and size: 1,250,000 shares @ $8.00 ($10,000,000) and 625,000 shares @ $8.00 ($5,000,000); total 1,875,000 shares for $15,000,000
- Transaction code: P (Purchase); footnote clarifies private placement from the issuer (F1)
- Record holders and structure: Shares held of record by OrbiMed Private Investments VII, LP ("OPI VII") and OrbiMed Genesis Master Fund, L.P. ("Genesis"); OrbiMed Advisors, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC are related entities described in footnotes F2–F3
- Joint filing and disclaimers: Report jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP; each disclaims beneficial ownership except to the extent of any pecuniary interest (F4)
- Board designation: OrbiMed designated Diyong Xu, an OrbiMed Advisors employee, as its representative to the issuer’s board (F4)
- Shares owned after transaction: Not specified in the provided filing text
- Timeliness: Reported on June 1, 2026 for May 28 transactions — filed within Form 4 timing rules (not marked late)
Context
- This is institutional purchasing by a reported 10% holder (OrbiMed-affiliated funds), not an individual executive. Institutional placements can reflect investor interest or financing arrangements rather than personal insider sentiment.
- Because the purchase was a private placement from the issuer (not an open-market buy), it may be tied to a financing or strategic investment rather than routine secondary-market buying.
Insider Transaction Report
Form 4
Q32 Bio Inc.QTTB
ORBIMED ADVISORS LLC
Director10% Owner
Transactions
- Purchase
Common Stock
[F1][F2][F4]2026-05-28$8.00/sh+1,250,000$10,000,000→ 3,502,987 total(indirect: See footnotes) - Purchase
Common Stock
[F1][F3][F4]2026-05-28$8.00/sh+625,000$5,000,000→ 625,000 total(indirect: See footnotes)
Footnotes (4)
- [F1]These shares of the Issuer's common stock were purchased from the Issuer in a private placement.
- [F2]These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
- [F3]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
- [F4]This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Diyong Xu, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.